Citation: | SUN Caihong, KONG Dongsheng, LIU Ruoyu, LIU Fang, ZHAO Kai, ZHAO Junyan. Comparison of clinical features and prognosis of oligodendroglioma versus astrocytoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(5): 536-539. DOI: 10.3969/j.issn.2095-5227.2022.05.008 |
[1] |
李朝晖,郭志钢,李庆伟. 弥漫性较低级别胶质瘤的整合性分子病理分型研究进展[J]. 中国肿瘤临床,2016,43(12): 541-544. doi: 10.3969/j.issn.1000-8179.2016.12.340
|
[2] |
Louis DN,Arie P,Pieter W,et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro-oncology,2021,23(8): 1231-1251. doi: 10.1093/neuonc/noab106
|
[3] |
Weller M,Pfister SM,Wick W,et al. Molecular neuro-oncology in clinical practice: a new horizon[J]. Lancet Oncol,2013,14(9): e370-e379. doi: 10.1016/S1470-2045(13)70168-2
|
[4] |
徐维林,王强,张宏伟,等. 长周期替莫唑胺治疗高级别胶质瘤生存期观察[J]. 解放军医学院学报,2016,37(7): 725-727. doi: 10.3969/j.issn.2095-5227.2016.07.015
|
[5] |
Stupp R,Mason WP,van den Bent MJ,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med,2005,352(10): 987-996. doi: 10.1056/NEJMoa043330
|
[6] |
Stupp R,Taillibert S,Kanner A,et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma[J]. JAMA,2017,318(23): 2306. doi: 10.1001/jama.2017.18718
|
[7] |
周苏娜,张琰君,何东杰,等. 低级别胶质瘤36例患者术后放疗的预后分析[J]. 山西医科大学学报,2016,47(9): 847-850.
|
[8] |
Bell EH,Zhang PX,Fisher BJ,et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial[J]. JAMA Oncol,2018,4(10): 1405-1409. doi: 10.1001/jamaoncol.2018.1977
|
[9] |
Lakomý R,Kazda T,Poprach A,et al. The role of chemotherapy in the treatment of low-grade gliomas[J]. Klin Onkol,2017,30(5): 343-348.
|
[10] |
朱巍,崔萌,马晓东. 岛叶低级别胶质瘤的生物学特性及预后评估[J]. 解放军医学院学报,2018,39(1): 5-8. doi: 10.3969/j.issn.2095-5227.2018.01.002
|
[11] |
Eckel-Passow JE,Lachance DH,Molinaro AM,et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors[J]. N Engl J Med,2015,372(26): 2499-2508. doi: 10.1056/NEJMoa1407279
|
[12] |
Tanriverdi T,Kemerdere R,Baran O,et al. Long-term surgical and seizure outcomes of frontal low-grade gliomas[J]. Int J Surg,2016,33(Pt A): 60-64.
|
[13] |
陈海南,莫立根,邓腾. MGMT基因对脑胶质瘤患者启动子甲基化变化的价值研究[J]. 中国实用神经疾病杂志,2016,19(6): 61-62. doi: 10.3969/j.issn.1673-5110.2016.06.040
|
[14] |
郭超. 脊髓胶质瘤MGMT基因启动子甲基化及蛋白表达对替莫唑胺敏感性的临床观察[D]. 唐山: 华北理工大学, 2016.
|
[15] |
Wijnenga MMJ,Mattni T,French PJ,et al. Does early resection of presumed low-grade glioma improve survival?A clinical perspective[J]. J Neurooncol,2017,133(1): 137-146. doi: 10.1007/s11060-017-2418-8
|
[16] |
Baumert BG,Hegi ME,van den Bent MJ,et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study[J]. Lancet Oncol,2016,17(11): 1521-1532. doi: 10.1016/S1470-2045(16)30313-8
|
[17] |
Kashi AS,Rakhsha A,Houshyari M. Overall survival in adult patients with low-grade, supratentorial glioma: ten years' follow up at a single institution[J]. Electron Physician,2015,7(3): 1114-1120.
|
1. |
吴小延,王苏杰,王芳,杜紫明,邓玲. IDH突变和1p/19q共缺失型少突胶质细胞瘤临床病理特征和预后分析. 肿瘤防治研究. 2024(03): 178-184 .
![]() |